Sign In
Buy KPTI
$9.00
-0.230 (-2.49%)
At Close: Jun 03, 2026
NEWTON, Mass., Dec. 11, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the National
NEWTON, Mass., Dec. 7, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced an oral presentati
NEWTON, Mass., Dec. 7, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that over twenty pr
Top Wall Street analysts are betting on these stocks heading into December
08:31am, Sunday, 29'th Nov 2020
TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Anaplan and Autodesk
Karyopharm Reports Positive Phase 3 SEAL Data in Oral Presentation at The Connective Tissue Oncology Society 2020 Annual Meeting
10:30am, Friday, 20'th Nov 2020
NEWTON, Mass., Nov. 20, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported it will present po
Karyopharm Is Extremely Cheap After Recent Sell-Off
04:36am, Monday, 16'th Nov 2020
Xpovio is showing good uptake after about a year on the market. The second line multiple myeloma indication will likely be added next Spring.
Karyopharm Therapeutics: Current Share Price Under-Reflects The Inherent Value
06:00am, Friday, 13'th Nov 2020
Recent advancements in readouts for Xpovio and Selinexor have yet to be reflected in market pricing, in our view. Karyopharm has had an in line quarter, where Xpovio sales were driven by new prescribe
Karyopharm Announces Publication of XPOVIO® (Selinexor) Phase 3 BOSTON Study Results in The Lancet
07:06pm, Thursday, 12'th Nov 2020
NEWTON, Mass., Nov. 12, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the results
Karyopharm Announces XPOVIO® (Selinexor) Clinical Data to be Presented at the American Society of Hematology 2020 Annual Meeting
01:16pm, Wednesday, 04'th Nov 2020
NEWTON, Mass., Nov. 4, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that twenty-one ab
Karyopharm Therapeutics, Inc. (KPTI) CEO Michael Kauffman on Q3 2020 Results - Earnings Call Transcript
08:34pm, Monday, 02'nd Nov 2020
Karyopharm Therapeutics, Inc. (KPTI) CEO Michael Kauffman on Q3 2020 Results - Earnings Call Transcript
Karyopharm Therapeutics, Inc. (KPTI) CEO Michael Kauffman on Q3 2020 Results - Quick Version Earnings Call Transcript
06:52pm, Monday, 02'nd Nov 2020
Karyopharm Therapeutics, Inc. (KPTI) CEO Michael Kauffman on Q3 2020 Results - Quick Version Earnings Call Transcript
Karyopharm Therapeutics: Q3 Earnings Insights
04:41pm, Monday, 02'nd Nov 2020
Shares of Karyopharm Therapeutics (NASDAQ:KPTI) increased 10.3% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share decreased 8.96% over the past year t
Apple Is Evaluating Scratch-Resistant Diamond Like Coatings On Gorilla Glass (NASDAQ:AAPL)
06:47pm, Wednesday, 07'th Oct 2020
Apple is evaluating methods to strengthen further its display Gorilla Glass by coating them with diamonds.
Week In Review: Antengene Approved By Hong Kong Exchange For $200 Million IPO
01:48pm, Sunday, 30'th Aug 2020
Antengene, a three-year old Shanghai startup originally backed by Celgene, will conduct a Hong Kong IPO that is expected to raise $200 million.
Oncology Stocks Area Trading Materially Lower The Last 2 Months
08:00am, Monday, 24'th Aug 2020
Of a pool of 26 oncology stocks we track, with 1 exception, all (literally 25 of 26) are trading materially lower from the third week of June 2020.
